We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 486.00
Bid: 340.00
Ask: 641.00
Change: 0.00 (0.00%)
Spread: 301.00 (88.529%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 486.00
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

9 Oct 2020 07:00

RNS Number : 5683B
Treatt PLC
09 October 2020
 

9 October 2020

TREATT PLC

("Treatt" or "the Group")

Trading update for the year ended 30 September 2020

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, today publishes a trading update for the year ended 30 September 2020 ("FY20").

Highlights

· FY20 profit before tax and exceptional items in line with pre-COVID-19 Board expectations.

· 16% revenue growth in our health & wellness category.

· Stronger margins from our focus on added-value products, despite the impact of lower orange oil prices and COVID-19.

· UK relocation project progressing well and on budget - transition expected in Spring 2021.

· Cautiously optimistic outlook for the new financial year despite on-going uncertainty from COVID-19.

FY20 performance

Building on the momentum seen in H1, the Group performed well during the second half of the financial year, reflecting our focus on added-value products. The Board expects to report profit before tax and exceptional items for FY20 of approximately £14m, in line with its pre-COVID-19 expectations.

Revenue for the year is anticipated to be in the region of £109m, a decrease of 3% (-3% in constant currency) compared with the prior year. As previously reported, revenue for the year was impacted by the substantial reduction in orange oil raw material input costs, which fell by more than 50% in the prior year. Excluding orange oil related products (which represent around 22% of FY20 revenue), revenue grew by 4% in the year. The impact of COVID-19 on on-trade demand was particularly felt in Q3, with Q4 revenue showing some recovery as the hospitality sectors in Europe and the US began to reopen.

Despite a 10% reduction in reported revenue from our citrus category, which contributes 50% (FY19: 54%) of Group revenue, gross profit from this category increased year on year as the business continues to transition away from traded and minimally processed products to more added-value customer solutions. In addition, the Group experienced increased demand for citrus co-products used in industrial and household cleaning products, as new cleaning protocols across the globe drove demand.

In non-citrus revenues; health & wellness (including sugar reduction and representing 7% of Group revenue; FY19: 6%) grew by 16% and fruit & vegetables (representing 7% of Group revenue; FY19: 6%) grew by 10% as the Group's clean label innovations continue to perform well in the marketplace.

A strong category for the Group in recent years has been tea (representing 6% of Group revenue; FY19: 6%) which grew revenue by 47% in H1. This category was materially affected by the loss of on-trade demand in H2 (including business to hospitality, bars, restaurants and cruise lines) and has consequently ended the year marginally down (-2%) against the prior year's revenue.

The Group's traditional range of herbs, spices & florals (representing 11% of Group revenue; FY19: 10%) grew revenue by 8% in the year. Whilst 'natural' now represents approximately 81% of the Group's portfolio, revenue from our aroma and high impact chemical category into the synthetic flavour and fragrance market remained broadly unchanged.

New product launches in our consumer markets have been less prevalent over the last six months due to COVID-19, however the Group continues to grow revenue from the alcoholic seltzer market*, which has increased significantly in the US over the last year (particularly through off-trade channels) and is now beginning to make inroads into Europe. The Group continues to invest in its natural coffee extract capabilities, which also represents a significant growth opportunity for the business.

We are pleased to confirm that construction work on our new facility in the UK is almost complete which means that we are approximately 75% of the way through our overall capital investment programme in the US and UK. The fitout of the new UK facility is under way and we expect to begin transitioning to the new site in Spring 2021.

As previously reported, the expansion of our US manufacturing facility was completed last year and is now fully operational. Our capacity for products in our fruit & vegetables, health & wellness and tea product categories doubled and came on stream in time for the new crop season, with growth in these categories expected to continue from both existing and new customers.

Cash and dividends

The cash performance for the Group was encouraging, with the Group remaining cash positive despite significant capital investment in our new UK facility. At the end of FY20 the Group had net cash of £1m (excluding lease liabilities) and total bank facilities of £20m. The Board confirms its intention to propose a final dividend in line with its unchanged dividend policy.

Outlook

As we begin our new financial year, the global impact of COVID-19 continues, and the wellbeing and safety of our colleagues remains our priority. Despite the significant disruption to consumer demand across our markets, we continue to diversify our revenues and position the Group as an added-value natural extracts and ingredients provider across a range of growth categories. As such, we are cautiously optimistic about our growth trajectory into FY21.

The build out of our coffee platform continues and we anticipate gaining traction in the cold brew coffee market. Additionally, we foresee continued benefit from the ongoing growth in the global alcoholic seltzer market.

The Group is well-positioned as a natural extracts business and we anticipate further growth across all our product categories. With additional capacity in the US and the forthcoming transition to our new UK facility, the Group enters the new financial year well placed, with the products, the people and the production capacity to optimise market opportunities.

Daemmon Reeve, CEO of Treatt, commented:

"We have delivered a strong performance in spite of the difficult backdrop during the year and I thank our colleagues across the Group for their skill, flexibility and determination in what has been an extraordinary period.

"Our strategy has built resilience into our business model and we are strongly positioned to benefit from key consumer trends including the preference for natural products, a growing interest in health and wellness, and premiumisation. As such, we remain confident in the long-term prospects for the business."

Treatt's results for the year ended 30 September 2020 are expected to be announced on 24 November 2020.

* The global alcoholic seltzer market size was valued at USD 4.4 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 16.2% from 2020 to 2027. Source: Grand View Research www.grandviewresearch.com.

 

Treatt plc +44 (0)1284 702500

Daemmon Reeve Chief Executive Officer

Richard Hope Chief Financial Officer

 

Broker

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

Alex Wright

 

Financial PR

MHP Communications +44 (0) 20 3128 8789

Tim Rowntree

Simon Hockridge

Catherine Chapman

 

About the Group

Treatt is a global, independent manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the flavour, fragrance and multinational consumer product industries, particularly in the beverage sector. Renowned for its technical expertise and knowledge of ingredients, their origins and market conditions, Treatt is recognised as a leader in its field.

 

The Group employs over 300 staff in Europe, North America and Asia and has manufacturing facilities in the UK and US. Its international footprint enables the Group to deliver powerful and integrated solutions for the food, beverage and fragrance industries across the globe.

 

 

For further information about the Group, visit www.treatt.com.

 

Information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and markets in which the Group operates. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated. No assurances can be given that the forward-looking statements in this announcement will be realised. The forward-looking statements reflect the knowledge and information available at the date of preparation of this announcement and the Group undertakes no obligation to update these forward-looking statements. Nothing in this announcement should be construed as a profit forecast.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGZMGGNRFGGZM
Date   Source Headline
10th Apr 20247:00 amRNSHalf Year Trading Update & Notice of Results
19th Mar 20243:40 pmRNSNotification of Transactions of Directors
4th Mar 20247:00 amRNSAppointment of Chief Executive Officer
13th Feb 20249:35 amRNSHolding(s) in Company
31st Jan 20242:41 pmRNSNotification of Transaction of PDMR
25th Jan 20243:49 pmRNSResult of AGM
25th Jan 20247:00 amRNSAGM Trading Update
23rd Jan 20241:57 pmRNSTotal Voting Rights
21st Dec 20232:07 pmRNSNotification of Transaction of Director
15th Dec 20236:09 pmRNSNotification of Transactions - Replacement
15th Dec 20234:42 pmRNSNotification of Transactions of Directors
13th Dec 20237:00 amRNSInterim Chief Financial Officer Appointment
12th Dec 20234:24 pmRNSAnnual Report and Notice of Annual General Meeting
1st Dec 20237:01 amRNSBlock Listing Six Monthly Return
1st Dec 20237:00 amRNSBlock Listing Six Monthly Return
28th Nov 20234:15 pmRNS2023 Final Dividend
28th Nov 20237:00 amRNSFull Year Results
20th Oct 20237:00 amRNSCEO Succession
10th Oct 20237:00 amRNSTrading Update
18th Sep 20234:11 pmRNSHolding(s) in Company
15th Aug 20234:14 pmRNSNotification of Transactions of Directors
28th Jul 202310:43 amRNSTotal Voting Rights
13th Jul 202312:15 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202311:09 amRNSNotification of Transaction of Director
21st Jun 20234:05 pmRNSNotification of Transactions of Director
12th Jun 20234:13 pmRNSDirector Declaration
7th Jun 20232:28 pmRNSBlock Listing Application
1st Jun 20237:00 amRNSBlock listing Six Monthly Return
19th May 20235:10 pmRNSHolding(s) in Company
19th May 20234:28 pmRNSHolding(s) in Company
9th May 20237:00 amRNSHalf Year Results
12th Apr 20237:00 amRNSHalf Year Trading Update and Notice of Results
20th Mar 20233:28 pmRNSNotification of Transactions of Directors
7th Mar 20233:25 pmRNSDirector/PDMR Shareholding
22nd Feb 20233:06 pmRNSHolding(s) in Company
21st Feb 202312:51 pmRNSNotification of Transactions of Director
21st Feb 202312:49 pmRNSNotification of Transactions of Director
20th Feb 202311:01 amRNSNotification of Transaction of a Director
30th Jan 20231:49 pmRNSHolding(s) in Company
27th Jan 20233:10 pmRNSResult of AGM
27th Jan 20237:00 amRNSAGM Trading Update
10th Jan 20235:05 pmRNSVoting Rights and Capital
28th Dec 20227:00 amRNSNotification of Transaction of Director
28th Dec 20227:00 amRNSAnnual Report and Notice of Annual General Meeting
20th Dec 202212:20 pmRNSBoard Appointment and Board Committee Changes
16th Dec 20221:25 pmRNSNotification of Transactions of Directors
1st Dec 20223:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20223:55 pmRNSBLOCK LISTING SIX MONTHLY RETURN
29th Nov 20224:36 pmRNSPrice Monitoring Extension
29th Nov 20227:10 amRNSFull Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.